The Paradigm Shift
Traditional medical research focuses on identifying and fixing what goes wrong in disease. At Halia Therapeutics, we’ve flipped that model—studying people who, despite carrying high-risk genetic mutations, remain healthy. By decoding these real-world cases of natural disease resistance, we uncover powerful insights into genetic resilience.
This bold shift in perspective enables us to identify new drug targets rooted in biology that work, not just in theory, but in real life. It opens the door to therapies that are not only more effective but safer, as they mimic the body’s own protective mechanisms. By starting with resilience instead of disease, we aim to change not only treatment but also the trajectory of human health.
What is Genetic Resilience?
Genetic resilience is the remarkable ability of some individuals to remain healthy despite carrying genes that typically predispose them to serious diseases. Their bodies naturally resist illness, and we’re uncovering how. By studying these resilient outliers, we identify protective biological mechanisms that help prevent disease before it starts. These insights guide the development of new therapies designed to work in conjunction with the body’s own defenses, redefining what is possible in medicine.
The Concept
Some individuals remain healthy despite carrying high-risk genetic variants like APOE4, BRCA1/2, or FTO.
Our Approach
We identify protective modifiers-genes or pathways that buffer the effects of disease associated variants.
The Opportunity
By reproducing the biology of resilient individuals, we can intercept disease before it manifests.
GENMOR Platform
How we find resistance
Our proprietary GENMOR platform analyzes in-depth family pedigrees and linked health records to uncover why some individuals remain healthy despite a high genetic risk. By comparing resilient individuals to those who develop disease, we identify the subtle biological differences that point to protective mechanisms.
This approach accelerates drug discovery by revealing real-world, human-validated targets, making the process faster, more innovative, and grounded in natural resilience.
Proof in the Pipeline
Programs in development
Our approach is already delivering results. We’ve advanced drug candidates for Alzheimer’s disease, myelodysplastic syndrome (MDS), and obesity—all now in clinical trials. These programs validate that our science translates beyond discovery into real patient impact.
Each therapy is built on a foundation of genetic resilience, guided by human biology, and driven by urgent medical need—proof that our platform is not just innovative, but actionable.
Accelerating Discovery with GENMOR-AI
Our GENMOR-AI platform rapidly analyzes massive datasets to pinpoint the strongest protective genetic factors behind disease resistance. As more data is collected, the system continuously improves, refining its insights and uncovering new targets with each cycle.
This adaptive learning approach enables us to identify high-potential drug candidates more quickly, reduce costly false starts, and apply discoveries across a broad range of diseases.
Why AI is Built for Halia
AI thrives on structured, high-quality data, and that’s precisely what we have. From multi-generational family trees to rich genetic and clinical records, our datasets are uniquely suited for uncovering the hidden biology behind disease resistance.
Unlike most companies trying to retrofit AI into healthcare, we built Halia from the ground up to integrate AI at every level, enabling faster, smarter, and more accurate decisions from the start.
“Halia Therapeutics isn’t just advancing medicine; we are unlocking human potential. By harnessing the power of genetic resilience, we go beyond treatment to create a future where longevity and vitality are within everyone’s reach. Our relentless pursuit of innovation, empowered by exclusive access to primary datasets and a patient-first approach, ensures that we don’t just add years to life, we add life to years.”
– Dr David Bearss, CEO